Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...
The global gene therapy market size is projected to expand significantly, with an estimated value of USD 19.3 billion by 2034 ...
A study on vector database and AI integration identifies unstable indexing, weak cross-modal fusion, and rigid resource ...
Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...
The science of gene therapy is enjoying a renaissance after ups and downs over the past 25 years. The heart of this field still largely relies on viral vector gene transfer systems that have evolved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results